Clearside Biomedical Inc (OQ:CLSD)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Apr 16, 2024 07:05 am ET

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the...

Apr 02, 2024 07:05 am ET

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024 07:05 am ET

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 12, 2024 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended...

Feb 29, 2024 07:05 am ET

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 07, 2024 08:00 am ET

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into...

Dec 14, 2023 07:05 am ET

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Nov 13, 2023 04:05 pm ET

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September...

Nov 08, 2023 07:05 am ET

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Nov 07, 2023 04:20 pm ET

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Nov 03, 2023 12:00 pm ET

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with...

Nov 02, 2023 07:05 am ET

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Nov 01, 2023 07:05 am ET

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Oct 31, 2023 07:05 am ET

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

Oct 16, 2023 07:05 am ET

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Oct 04, 2023 09:00 am ET

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in C

ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that...

Oct 03, 2023 04:35 pm ET

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

Sep 19, 2023 07:05 am ET

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Aug 14, 2023 04:05 pm ET

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30,...

Aug 02, 2023 04:30 pm ET

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will participate in the following investor...

Aug 01, 2023 07:05 am ET

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

Jul 31, 2023 07:05 am ET

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientif

Jul 20, 2023 07:05 am ET

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

Jul 17, 2023 07:05 am ET

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Jul 11, 2023 04:05 pm ET

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

Jul 10, 2023 07:05 am ET

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that the Therapeutic Goods Administration (TGA) of Australia...

Jun 01, 2023 07:05 am ET

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

May 11, 2023 07:05 am ET

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31,...

May 09, 2023 04:30 pm ET

Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

May 02, 2023 07:05 am ET

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

Apr 27, 2023 07:05 am ET

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Apr 19, 2023 07:05 am ET

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Apr 18, 2023 07:05 am ET

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Apr 12, 2023 07:05 am ET

Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

Apr 05, 2023 07:05 am ET

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Arshad M. Khanani, M.D., M.A,...

Mar 09, 2023 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended...

Feb 23, 2023 07:05 am ET

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

Feb 21, 2023 07:05 am ET

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

Feb 07, 2023 07:05 am ET

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that data from the Company’s OASIS Phase 1/2a clinical...

Feb 06, 2023 07:30 am ET

Clearside Biomedical Announces Leadership Team Update

Feb 02, 2023 07:05 am ET

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive results from the Extension Study of its OASIS...

Nov 22, 2022 07:05 am ET

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following...

Nov 17, 2022 07:30 am ET

Thinking about buying stock in Macy's, Immunic, LexinFintech, Provention Bio, or Clearside Biomedical?

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, IMUX, LX, PRVB, and CLSD.

Nov 10, 2022 07:50 am ET

Thinking about buying stock in Digital Turbine, Purple Innovation, Clearside Biomedical, Rivian Automotive, or ZipRecruiter?

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APPS, PRPL, CLSD, RIVN, and ZIP.

Nov 10, 2022 07:05 am ET

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s...

Nov 09, 2022 07:15 am ET

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September...

Nov 09, 2022 07:05 am ET

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patien

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive results from its OASIS Phase 1/2a clinical...

Nov 08, 2022 04:05 pm ET

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company will host a conference call on...

Nov 02, 2022 07:05 am ET

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be...

Oct 04, 2022 07:05 am ET

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered...

Sep 27, 2022 07:05 am ET

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer...

Aug 25, 2022 07:05 am ET

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer...

Aug 09, 2022 07:05 am ET

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30,...

Aug 08, 2022 04:30 pm ET

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today it has entered into a Royalty Interest Purchase and...

Aug 03, 2022 07:05 am ET

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following...

Jul 27, 2022 07:05 am ET

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2022 financial results will be...

Jul 26, 2022 07:05 am ET

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today completion of dosing in Cohorts 3 and 4 of OASIS, its...

Jul 07, 2022 07:05 am ET

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

Jun 14, 2022 07:05 am ET

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

Jun 08, 2022 07:05 am ET

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

May 11, 2022 04:05 pm ET

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31,...

May 05, 2022 07:05 am ET

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology

Apr 29, 2022 07:05 am ET

Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2022 financial results will be...

Apr 06, 2022 07:05 am ET

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

Mar 28, 2022 09:31 am ET

Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners?

NEW YORK, March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP.

Mar 28, 2022 06:59 am ET

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associat

XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection

Mar 28, 2022 06:59 am ET

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associat

XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection

Mar 11, 2022 07:47 am ET

Thinking about buying stock in Clearside Biomedical, Pearson, Paramount Gold Nevada, Hycroft Mining, or Alto Ingredients?

NEW YORK, March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, PSO, PZG, HYMC, and ALTO.

Mar 10, 2022 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended...

Mar 03, 2022 07:05 am ET

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors

Mar 01, 2022 07:05 am ET

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022

Feb 25, 2022 07:05 am ET

Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2021 financial...

Feb 14, 2022 04:05 pm ET

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

Feb 02, 2022 07:05 am ET

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that Clearside’s SCS injection platform featuring the...

Dec 21, 2021 07:05 am ET

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive safety results from OASIS, its ongoing Phase...

Dec 13, 2021 04:05 pm ET

Clearside Biomedical Added to the Nasdaq Biotechnology Index

Nov 16, 2021 07:05 am ET

Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple presentations were given at the American...

Nov 11, 2021 07:05 am ET

Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it will participate in the following investor...

Nov 10, 2021 04:05 pm ET

Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September...

Oct 28, 2021 07:05 am ET

Clearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2021 financial results will be...

Oct 25, 2021 06:45 am ET

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveiti

XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid

Oct 25, 2021 06:45 am ET

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveiti

Oct 13, 2021 07:05 am ET

Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations...

Oct 04, 2021 07:05 am ET

Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting

Sep 21, 2021 07:05 am ET

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Sep 09, 2021 07:05 am ET

Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries

Aug 23, 2021 04:05 pm ET

Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum

Aug 15, 2021 08:00 pm ET

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the licensed territory for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERE™ in the U.S.) from Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to also include ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Phili

Aug 10, 2021 04:05 pm ET

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments...

Aug 04, 2021 07:05 am ET

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

Jul 27, 2021 04:05 pm ET

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

Jun 25, 2021 09:31 am ET

Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?

NEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.

Jun 17, 2021 08:31 am ET

Thinking about buying stock in Clearside Biomedical, Acorda Therapeutics, Orphazyme, Nano-X Imaging, or Satsuma Pharmaceuticals?

NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, ACOR, ORPH, NNOX, and STSA.

Jun 15, 2021 10:50 am ET

Thinking about buying stock in Clearside Biomedical, Uxin, Petco Health and Wellness, Ashford Hospitality Trust, or Uber?

NEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, UXIN, WOOF, AHT, and UBER.

Jun 15, 2021 07:05 am ET

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Jun 09, 2021 07:05 am ET

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

Jun 02, 2021 06:59 am ET

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

PDUFA Action Date Is October 30, 2021

May 17, 2021 04:05 pm ET

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in June 2021 - - Multiple ARVO Presentations Highlight Suprachoroidal Delivery with SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -...

May 10, 2021 07:05 am ET

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

May 04, 2021 07:05 am ET

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

May 03, 2021 07:05 am ET

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New...

Apr 05, 2021 07:05 am ET

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

Mar 10, 2021 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 02, 2021 07:05 am ET

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Feb 24, 2021 07:05 am ET

Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021

Feb 23, 2021 07:05 am ET

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

Feb 16, 2021 07:05 am ET

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

Feb 08, 2021 07:05 am ET

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

Jan 12, 2021 07:05 am ET

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Jan 08, 2021 08:31 am ET

Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?

NEW YORK, Jan. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL.

Jan 06, 2021 07:05 am ET

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

Jan 05, 2021 07:30 am ET

Thinking about buying stock in Aileron Therapeutics, Check Cap, Jaguar Health, Clearside Biomedical, or Gritstone Oncology?

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALRN, CHEK, JAGX, CLSD, and GRTS.

Jan 04, 2021 07:30 am ET

Thinking about buying stock in Ocugen, BioNano Genomics, FLIR Systems, Clearside Biomedical, or Viewray?

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, BNGO, FLIR, CLSD, and VRAY.

Nov 16, 2020 07:05 am ET

Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Scie

Nov 11, 2020 07:05 am ET

Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference

Nov 10, 2020 04:05 pm ET

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Oct 30, 2020 07:05 am ET

Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020

Sep 23, 2020 07:05 am ET

Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina

Sep 11, 2020 08:30 am ET

Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery

Sep 09, 2020 04:05 pm ET

Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference

Sep 09, 2020 08:30 am ET

Clearside Biomedical’s Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery

Aug 26, 2020 07:05 am ET

Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe

Aug 10, 2020 04:05 pm ET

Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs -- Engaged New Contract Manufacturer for XIPERE™ -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE...

Aug 10, 2020 04:02 pm ET

Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug...

Aug 04, 2020 07:05 am ET

Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Jul 30, 2020 07:05 am ET

Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020

Jul 27, 2020 07:05 am ET

Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple posters and...

Jun 17, 2020 07:05 am ET

Clearside Biomedical Announces Numerous Presentations at the ARVO 2020 Meeting

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral...

May 08, 2020 07:05 am ET

Clearside Biomedical Announces First Quarter 2020 Financial Results

Apr 28, 2020 07:05 am ET

Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health

Apr 22, 2020 07:05 am ET

Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors

Apr 09, 2020 07:05 am ET

Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians

Apr 08, 2020 07:05 am ET

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

Mar 11, 2020 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Partners Expected to Initiate Clinical Testing in 2020 for Treatment of Wet AMD, Diabetic Retinopathy and Ocular Cancer Using SCS Microinjector™ -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 11,...

Mar 11, 2020 04:04 pm ET

Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay,...

Mar 11, 2020 04:03 pm ET

Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company...

Feb 27, 2020 07:05 am ET

Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020

Feb 26, 2020 07:05 am ET

Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020

Feb 25, 2020 07:05 am ET

Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral...

Feb 05, 2020 07:05 am ET

Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society Conferences

Jan 28, 2020 06:00 am ET

Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the randomized, controlled, double-masked Phase 3 clinical trial (PEACHTREE stu

Jan 06, 2020 07:05 am ET

Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference

Nov 13, 2019 04:05 pm ET

Clearside Biomedical to Present at the Stifel 2019 Healthcare Conference

Nov 06, 2019 04:05 pm ET

Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Oct 30, 2019 04:05 pm ET

Clearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 2019

Oct 30, 2019 07:05 am ET

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

Oct 23, 2019 06:55 am ET

Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis

NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020

Oct 23, 2019 06:55 am ET

Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis

NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020

Oct 17, 2019 04:05 pm ET

Clearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral...

Oct 03, 2019 07:05 am ET

Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

Sep 19, 2019 07:05 am ET

Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous presentations...

Sep 04, 2019 07:00 am ET

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

ROCKVILLE, Md. and ALPHARETTA, Ga., Sept. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today announced an option and license agreement for exclusive worldwide rights to Clearside's proprietary, in-office SCS Mi

Sep 03, 2019 04:05 pm ET

Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference

Aug 22, 2019 07:05 am ET

Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update regarding the...

Aug 07, 2019 04:05 pm ET

Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 06, 2019 04:35 pm ET

Clearside Biomedical to Present at the 2019 Wedbush PacGrow Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer,...

Jul 31, 2019 04:30 pm ET

Clearside Biomedical to Report Second Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, August 7, 2019

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its second quarter 2019 financial results will be...

Jul 31, 2019 07:05 am ET

Clearside Biomedical Announces Multiple Oral Presentations Delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting

Jul 18, 2019 07:05 am ET

Clearside Biomedical Announces Multiple Oral Presentations to be Given at the American Society of Retinal Specialists (ASRS) Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations on Clearside’s pipeline...

Jul 09, 2019 07:05 am ET

Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced its entry into a worldwide licensing agreement with Aura...

Jun 11, 2019 07:05 am ET

Clearside Biomedical to Present at the JMP Securities Life Sciences Conference

May 15, 2019 07:05 am ET

Clearside Biomedical to Present at the UBS Global Healthcare Conference

May 08, 2019 07:05 am ET

Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and...

May 01, 2019 07:05 am ET

Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations were made on Clearside’s...

Apr 25, 2019 07:05 am ET

Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its first quarter 2019 financial results will be...

Apr 18, 2019 07:05 am ET

Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations will be made on Clearside’s...

Apr 15, 2019 07:30 am ET

New Research: Key Drivers of Growth for FedEx, Clearside Biomedical, Aaron's, Lumber Liquidators, Timken, and Novanta — Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX), Clearside Biomedical, Inc. (NASDAQ:CLSD),...

Apr 08, 2019 07:05 am ET

Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO

Apr 02, 2019 04:05 pm ET

Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference

Mar 12, 2019 04:05 pm ET

Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the fourth quarter and year ended...

Mar 04, 2019 07:05 am ET

Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference

Feb 27, 2019 07:05 am ET

Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019

Feb 21, 2019 08:31 am ET

Thinking about buying stock in ARCA biopharma, Clearside Biomedical, Kandi Technologies, Nike or Tahoe Resources?

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABIO, CLSD, KNDI, NKE, and TAHO.

Feb 20, 2019 07:35 am ET

Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (NASDAQ:CSCO), Zendesk, Inc. (NYSE:ZEN), Clearside...

Feb 20, 2019 07:05 am ET

Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19,

Feb 19, 2019 07:05 am ET

Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations were given at the 42nd...

Jan 20, 2019 11:15 am ET

Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose

Jan 02, 2019 08:00 am ET

Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel...

Dec 19, 2018 04:05 pm ET

Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has submitted a New Drug Application (“NDA”) for...

Nov 27, 2018 08:25 am ET

Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc. (NASDAQ:FSCT), GNC Holdings, Inc....

Nov 08, 2018 07:00 am ET

Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended September 30,...

Nov 07, 2018 04:30 pm ET

Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel...

Nov 05, 2018 04:30 pm ET

Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results will be...

Nov 05, 2018 07:00 am ET

Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that the primary endpoint was not achieved in its Phase...

Oct 29, 2018 10:25 am ET

Presentation of Additional Analyses of Clearside’s PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE™ in Treating Uveitic Macular Edema

Oct 25, 2018 08:00 am ET

Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A. to the...

Oct 22, 2018 04:30 pm ET

CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018

Oct 19, 2018 08:00 am ET

Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford, CSCP, as Vice...

Oct 16, 2018 07:30 am ET

Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearside Biomedical, Inc. (NASDAQ:CLSD), JELD-WEN Holding, Inc....

Sep 26, 2018 04:30 pm ET

Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that Jeffrey Edwards has been appointed to its Board of...

Sep 18, 2018 04:30 pm ET

Positive PEACHTREE Data to be Highlighted at EURETINA 2018

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of...

Sep 13, 2018 08:00 am ET

Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of...

Sep 12, 2018 04:30 pm ET

Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position...

Sep 11, 2018 04:30 pm ET

Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Leslie Zacks as General Counsel and...

Sep 10, 2018 04:30 pm ET

Clearside Biomedical to Participate in 2018 Janney Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel...

Sep 06, 2018 04:30 pm ET

Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality

Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President,...

Aug 17, 2018 08:15 am ET

Analysis: Positioning to Benefit within Armstrong Flooring, U.S. Global Investors, Aqua Metals, Clearside Biomedical, EP Energy, and Avadel Pharmaceuticals — Research Highlights Growth, Revenue, and C

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong Flooring, Inc. (NYSE:AFI), U.S. Global Investors, Inc....

Aug 09, 2018 08:00 am ET

Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel...

Aug 08, 2018 07:00 am ET

Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended June 30, 2018 and...

Aug 01, 2018 08:00 am ET

Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its second quarter 2018 financial results will be...

Ad blocking detected

Clearside Biomedical Inc (OQ:CLSD)

Business Focus: Bio Therapeutic Drugs